Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study
There are limited well-controlled studies that conclusively demonstrate a benefit of adjuvant therapy in resected perihilar cholangiocarcinoma. Most studies include all biliary tract tumors as one entity despite the heterogeneity of these diseases.
We identified patients with resected perihilar cholangiocarcinoma from the National Cancer Database between 2006 and 2013. Patients who received adjuvant therapy (AT) were compared to an observation (OB) cohort by propensity score matching.
We identified 1846 patients: 1053 patients (57%) in the OB group, and 793 (43%) in the AT group. Patients who received adjuvant therapy were more likely to be younger, have a higher rate of private insurance, have higher T and N stage tumors, and were more likely to have positive resection margins. After 1:1 propensity score matching, 577 OB group patients were compared with 577 AT group patients. The AT cohort was associated with better overall survival compared with the OB cohort (hazard ratio [HR] 0.73; 95% confidence interval [CI] 0.64–0.83). The median survival was 29.5 and 23.3 months for the AT and OB groups, respectively (P < 0.01). Subgroup analysis demonstrated a survival advantage for adjuvant therapy in disease with positive resection margins (HR 0.53; 95% CI 0.42–0.67).
Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma, especially in disease with positive resection margins. This study supports the use of adjuvant therapy in high-risk patients.
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001105. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. RMM is the Alvin Baldwin, Jr. Chair in Surgery. MRP is the Dedman Family Scholar in clinical care. SCW is a UT Southwestern Disease-Oriented Clinical Scholar. The authors would like to thank Helen Mayo from the UT Southwestern Health Sciences Digital Library and Learning Center for assistance with literature searches, and Dave Primm for help in editing this manuscript.
The National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001105.
All authors have no disclosures.
- 1.Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73 discussion 473–5. https://doi.org/10.1097/00000658-199610000-00005.
- 14.Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. postoperative radiotherapy does not improve survival. Ann Surg. 1995;221(6):788–97; discussion 797–8.Google Scholar
- 20.Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22. https://doi.org/10.1200/jco.2014.60.2219.CrossRefPubMedGoogle Scholar
- 25.NCCN Clinical Practice Guidlines in Oncology. Hepatobiliary cancers. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary_blocks.pdf. Accessed 6 Feb 2017.
- 26.National Cancer Data Base. https://www.facs.org/quality%20programs/cancer/ncdb. Published July 4, 2016. Accessed 4 July 2016.
- 33.R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet], 2015. https://www.R-project.org/; Ref2 Sekhon J: Multivariate and Propensity Score Matching Software with Automated Balance Optimization: The Matching Package for R. J Stat Softw 42:1–52.
- 37.Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.| 2017 Gastrointestinal Cancers Symposium Abstracts.Google Scholar